XRAY

Dentsply Sirona

$8.95

-2.35%
Nov 16, 2026
Bobby Quantitative Model
Dentsply Sirona is one of the world's largest manufacturers of dental equipment, consumables, and laboratory products, formed by the 2016 merger of equals between Dentsply International and Sirona Dental Systems; it sells CAD/CAM and imaging technology, implants, orthodontic and endodontic products, and distributes roughly two-thirds of its consumables and equipment through third-party distributors. The company is a scaled incumbent in a consolidated dental oligopoly alongside Envista and Align, but its identity is increasingly that of a challenged turnaround rather than a growth compounder, with a broad portfolio that spans high-tech equipment and lower-margin consumables. The current investor narrative centers on persistent execution problems: the Q3 2026 earnings miss, disclosed on November 5, 2026, was accompanied by weak performance in orthodontics and implants, and the stock has been punished for soft dental demand and margin compression even as management points to steady guidance. Debate now hinges on whether cost discipline and portfolio rationalization can stabilize earnings before competitive share loss in implants and clear-aligner-adjacent categories becomes structural, with the depressed share price and a small residual dividend keeping a contingent of value and income investors engaged.

People also watch

Intuitive Surgical

Intuitive Surgical

ISRG

Analysis
Becton Dickinson

Becton Dickinson

BDX

Analysis
ResMed

ResMed

RMD

Analysis
Modernland Realty Ltd

Modernland Realty Ltd

MDLN

Analysis
West Pharmaceutical Services (United States)

West Pharmaceutical Services (United States)

WST

Analysis

BobbyInvestment Opinion: Should I buy XRAY Today?

Rating: Hold, with a speculative value tilt. The core thesis is that XRAY is a deep-value, cash-generative dental incumbent trading at 0.62x sales and 1.70x book — roughly a 90% de-rating from the 7x+ PS multiple of 2023 — where the market has already priced severe pessimism, but the absence of a published consensus price target and a ratings skew of only two positive actions out of ten (UBS Buy, Barrington Outperform versus Barclays Underweight and JP Morgan reiterating Neutral the day after the Q3 miss) means the Street offers no directional anchor. Consensus FY EPS of $1.25 (tight $1.23-$1.28 range) and revenue of $3.65 billion imply stabilization, not recovery, so the risk/reward is asymmetric but unconfirmed.

Supporting evidence is mixed but tilts toward the valuation floor holding. The primary metric is 0.62x PS against 1.70x book and 9.70x price-to-cash-flow, with a 5.62% dividend yield and $103 million of TTM free cash flow despite negative trailing EPS of -$0.26. Gross margin of 52.99% in Q3 2026 improved from 48.78% a year earlier, showing product economics are intact, while the 4.43% operating margin and $363 million of SG&A identify cost structure — not demand destruction — as the swing factor. The offsetting data are revenue contraction of 7.52% YoY to $836 million, a sequential slide from $898 million in Q2, and interest coverage of just 1.48x ($37 million operating income against $25 million interest expense) on 1.84x debt-to-equity.

Three risks could invalidate the thesis: orthodontics and implant weakness proving structural rather than cyclical, a dividend cut given the negative payout ratio of -0.21, and refinancing pressure if EBITDA stays depressed. This Hold would upgrade to Buy if revenue growth turns positive and operating margin recovers above roughly 8% (the Q2 2026 level of 9.13% is the proof point), or if the stock reclaims the $10.50-$11.00 resistance zone on volume; it would downgrade to Sell on a decisive break below the $8.42 October low or FY revenue tracking toward the $3.59 billion low estimate. Valuation verdict: deeply undervalued relative to its own history (PS down from 2.37x at year-end 2025 and 7x+ in 2023) and at a steep discount to profitable med-tech peers, but fairly-to-appropriately priced if the current earnings trajectory persists — the discount is compensation for execution risk, not a free lunch.

Sign up to view all

XRAY 12-Month Price Forecast

The forward view is genuinely two-sided: the valuation embeds severe pessimism, but the operating trend has not yet turned. Consensus EPS of $1.25 on revenue of $3.65 billion assumes stabilization, and the tight sub-5% estimate spread shows analysts agree on the near-term numbers even while ratings skew cautious — only two of ten recent actions are positive, and JP Morgan reiterated Neutral the day after the Q3 miss. The 5.62% dividend yield and $103 million TTM free cash flow provide a floor, but zero Q3 free cash flow and 1.48x interest coverage mean the cushion is thinner than the yield suggests. I would upgrade to bullish on two consecutive quarters of positive revenue growth with operating margin above 8%, or on a volume-confirmed reclaim of $10.50-$11.00; I would downgrade to bearish on a break below $8.42 or FY revenue guidance cut toward $3.59 billion. Absent either, the base case of range-bound trading between roughly $9 and $11.50 is the highest-probability outcome at 55%.

Historical Price
Current Price $8.95
Average Target $8.95
High Target $10.29
Low Target $7.60

Wall Street consensus

Coverage is moderate, with 8 analysts contributing estimates, and the sentiment is decidedly cautious. The institutional ratings history shows a clear skew: of ten recent actions, only two are positive (UBS at Buy, Barrington Research at Outperform), while the rest are Neutral or Market Perform (JP Morgan, Mizuho, Leerink, Piper Sandler, BMO) with Barclays maintaining an Underweight stance as recently as August 2026. No firm has upgraded in the visible window, and the most recent action — JP Morgan reiterating Neutral on November 6, 2026, the day after the Q3 miss — suggests analysts are holding fire rather than turning positive. Consensus EPS estimates average $1.25 (range $1.23-$1.28) on average revenue of $3.65 billion (range $3.59-$3.72 billion), implying the Street expects stabilization but not a sharp rebound. A precise average price target is not available in the provided data, so implied upside cannot be calculated; however, the tight EPS estimate range (a spread of under 5%) signals low conviction dispersion on near-term numbers even as the ratings skew bearish. The target range and its implications are therefore only partially observable. The high-end revenue estimate of $3.72 billion assumes orthodontics and implants stabilize and equipment demand holds, while the low end of $3.59 billion prices continued share loss and soft dental spending. The wide gap between the bullish outliers (UBS Buy, Barrington Outperform) and the bears (Barclays Underweight) reflects genuine disagreement about whether this is a cyclical trough or a structural decline — a split that, combined with the absence of a published consensus target, means investors should treat the analyst community as offering limited directional signal and rely on the company's own guidance and cash-flow trajectory for confirmation.

Drowning in data?

Find the real signal!

Bulls vs Bears: XRAY Investment Factors

The bear case currently carries stronger evidence: revenue is contracting 7.52% YoY, the Q3 miss came from the highest-value segments (orthodontics and implants), trailing earnings are negative, and leverage at 1.84x debt-to-equity with 1.48x interest coverage leaves little room for error. The bull case rests almost entirely on valuation — 0.62x sales and 1.70x book are deep-value levels that embed severe pessimism — plus intact ~53% gross margins that suggest the problem is cost structure, not product relevance. The single most important tension is whether the orthodontics and implant weakness is a cyclical trough in dental spending or structural share loss to competitors like Envista and Align; if cyclical, the depressed multiple re-rates sharply on any margin recovery, but if structural, the cheap valuation is a value trap. Until the stock reclaims the $10.50-$11.00 zone and revenue growth turns positive, the weight of evidence favors caution over conviction.

Bullish

  • Deep value at 0.62x sales: XRAY trades at just 0.62x price-to-sales and 1.70x book, versus a PS ratio of 2.11x in Q3 2026 and over 7x as recently as 2023 — a roughly 90% de-rating in three years. The market is pricing severe pessimism, leaving substantial re-rating room if margins merely normalize toward historical levels.
  • Gross margin holding near 53%: Q3 2026 gross margin of 52.99% improved from 48.78% in Q3 2025 and remains respectable for med-tech hardware, showing the core product economics are intact. The problem is a 4.43% operating margin, which means cost structure and SG&A ($363 million) are the lever — a fixable issue rather than a broken product.
  • Short-term momentum turning up: The stock is up 8.53% over the past month versus SPY's -2.26%, a +10.79 point relative-strength swing, and it has bounced off the October 19 low of $8.42. This suggests the selling may be exhausting and a basing pattern is forming near the floor of the 52-week range.
  • Street expects stabilization, not collapse: Consensus FY EPS of $1.25 (tight $1.23-$1.28 range, under 5% spread) and revenue of $3.65 billion imply analysts see earnings stabilizing rather than deteriorating. Two positive outliers (UBS Buy, Barrington Outperform) show some credible voices see a cyclical trough rather than structural decline.

Bearish

  • Revenue contracting 7.5% YoY: Q3 2026 revenue of $836 million fell 7.52% from $904 million a year earlier, and the sequential path ($880M → $898M → $836M) shows deceleration into the latest quarter. The miss was driven by orthodontics and implants — the higher-growth, higher-multiple segments — meaning the mix is tilting toward slower legacy consumables.
  • Leverage with thin interest coverage: Debt-to-equity is 1.84x with total debt at roughly 63% of capitalization, and Q3 interest coverage of just 1.48x ($37 million operating income against $25 million interest expense) leaves almost no cushion. A $29 million tax charge against $26 million pre-tax income wiped out the quarter, producing a -$2 million net loss.
  • Negative trailing earnings and ROE: Trailing EPS of -$0.26, net margin of -16.25%, and ROE of -44.63% reflect the large 2025 impairments (Q3 2025 net loss of $427 million, Q4 2025 loss of $146 million). The trailing PE of -3.81x and EV/EBITDA of -96.11x are meaningless, underscoring how far profitability has deteriorated.
  • Broken chart, -42.64% drawdown: The stock is down 16.35% over one year and 18.72% YTD versus SPY's +12.27%, a -28.62 point relative-strength gap, with a max drawdown of -42.64%. At $9.16 it sits at only ~13% of its 52-week range, and the 3-month change of -20.97% confirms the intermediate trend remains decisively negative.

XRAY Technical Analysis

XRAY is in a sustained, multi-quarter downtrend that has only recently shown tentative stabilization. The stock is down 16.35% over the past year and 18.72% year-to-date, versus a 12.27% gain for SPY over the same twelve months, a relative-strength gap of -28.62 percentage points. Against a 52-week range that runs from a low of roughly $8.42 (set October 19, 2026) to a high of about $14.27 (August 4, 2026), the current $9.16 price sits at only about 13% of the range — closer to the floor than the ceiling, which flags a broken chart rather than a momentum leader, though the recent bounce off the lows hints at basing rather than free-fall. Momentum is diverging sharply by timeframe. The 1-month change is +8.53%, a notable counter-trend rally that produced +10.79 points of relative strength versus SPY's -2.26% month, yet the 3-month change is -20.97% and the 6-month change is -9.04%, meaning the intermediate trend remains decisively negative. This pattern — a violent short-term bounce inside a falling intermediate trend — is classic oversold mean reversion, and the November 4 spike to $10.65 followed by a slide back to $9.16 suggests the rally is already losing steam; without volume data (reported as zero) confirmation is weak, so the bounce should be treated as suspect until price reclaims the $10.50-$11.00 zone. Key levels are well defined. Support sits at the $8.42-$8.56 October floor, and a breakdown there would signal a fresh leg lower and likely invite capitulation selling; resistance is the $14.05-$14.27 August ceiling, and a breakout above it would be required to call the downtrend over. The maximum drawdown of -42.64% over the period underscores how punishing the decline has been, and while beta is not provided, the stock's realized volatility — a 42% peak-to-trough decline against a flat-to-up market — implies materially higher risk than the index, warranting smaller position sizing and wider stops for anyone attempting to catch this falling knife.

Beta

—

—

Max Drawdown

-42.6%

Largest decline past year

52-Week Range

—

Price range past year

Annual Return

-15.0%

Cumulative gain past year

PeriodXRAY ReturnS&P 500
1m+4.4%-3.0%
3m-19.5%-3.6%
6m-9.1%-0.2%
1y-15.0%+10.1%
ytd-20.6%+8.5%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

XRAY Fundamental Analysis

The revenue trajectory is contracting, not growing. Q3 2026 revenue of $836 million fell 7.52% year-over-year from $904 million in Q3 2025, and the sequential path — $880 million in Q1, $898 million in Q2, $836 million in Q3 — shows deceleration into the most recent quarter. Segment data reinforce the weakness: Technologies and Equipment generated $548 million and Consumables $430 million, but the Q3 miss was attributed specifically to softness in orthodontics and implants, the higher-growth, higher-multiple parts of the portfolio, meaning the mix is tilting toward slower-growing legacy consumables. With consensus FY revenue estimates near $3.65 billion, the company needs a sharp second-half recovery to hit guidance, and the current trend implies downside risk to those numbers. Profitability is thin and volatile. Q3 2026 net income was -$2 million (a -0.24% net margin) on gross margin of 52.99%, a modest improvement from the 48.78% gross margin in Q3 2025 but a step down from Q2 2026's 54.90%. Operating income of $37 million (4.43% operating margin) was crushed by $25 million of interest expense and a $29 million tax charge against just $26 million of pre-tax income, and the trailing picture is worse — trailing EPS of -$0.26 and ROE of -44.63% reflect the large 2025 impairments (Q3 2025 net loss of $427 million, Q4 2025 loss of $146 million). Gross margins near 50-53% are respectable for med-tech hardware, but a mid-single-digit operating margin is far below what a scaled dental franchise should earn, pointing to cost structure and pricing problems rather than a gross-margin issue. The balance sheet is the central risk. Debt-to-equity stands at 1.84x with total debt at roughly 63% of capitalization, and interest coverage of just 1.48x in Q3 leaves little cushion if EBITDA stays depressed. Free cash flow is weak and lumpy — $103 million TTM, with Q3 2026 FCF of zero after $32 million of capex against $32 million of operating cash flow, and Q1 2026 FCF of -$12 million — while the current ratio of 1.51x and cash of $195 million provide adequate but not comfortable liquidity. The company is not self-funding growth at current cash generation levels and remains dependent on refinancing and modest divestiture proceeds, a precarious position for a business that still carries a dividend.

Quarterly Revenue

$836000000.0B

2026-09

Revenue YoY Growth

-7.5%

YoY Comparison

Gross Margin

53.0%

Latest Quarter

Free Cash Flow

$103000000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Technologies And Equipment
Consumables Segment

Open an Account, get $2 TSLA now!

Valuation Analysis: Is XRAY Overvalued?

Because trailing net income is negative (EPS of -$0.26, trailing PE of -3.81x), the PE ratio is not meaningful and I am leading with the price-to-sales ratio of 0.62x, supplemented by the forward PE of roughly 0.12x on the $1.25 consensus EPS estimate — a figure so low it implies the market is pricing severe earnings degradation or that the estimate is not comparable to the current share count. The 0.62x PS multiple is the cleaner signal: it says investors are paying about 62 cents for every dollar of revenue, a deep-value multiple that embeds skepticism about margin recovery. The forward PE of 0.12x versus a trailing PE of -3.81x is not a normal growth-expectation gap but a reflection of depressed trailing earnings; the market is effectively saying normalized earnings power is uncertain, not that explosive growth is coming. Peer comparison is constrained by the absence of an explicit industry-average multiple in the provided valuation data, but the internal evidence is telling: the stock trades at 1.70x book and 9.70x price-to-cash-flow, with an EV/EBITDA of -96.11x that is meaningless given negative EBITDA. Against a healthcare supplies sector where profitable med-tech peers typically command mid-teens to low-twenties earnings multiples, XRAY's 0.62x sales and 1.70x book represent a steep discount — one justified by negative net margin (-16.25%), a 6.85% operating margin, and ROE of -44.63%, but also one that leaves room for re-rating if margins normalize. Historical context confirms the stock is near the bottom of its own valuation band. The PS ratio has compressed from 2.11x in Q3 2026's reported history and 2.37x at year-end 2025 to the current 0.62x, and from over 7x as recently as 2023 — a roughly 90% de-rating in three years. Price-to-book has fallen from 2.27x at the end of 2023 to 1.70x today. This is either a deep value opportunity if the turnaround takes hold or a value trap if orthodontics and implant share loss proves structural; the market is currently pricing the latter.

PE

-3.8x

Latest Quarter

vs. Historical

Low-End

5-Year PE Range 15x~38x

vs. Industry Avg

40.3x

Industry PE ~40.3x*

EV/EBITDA

-96.1x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks are acute. Debt-to-equity of 1.84x with total debt near 63% of capitalization and Q3 interest coverage of only 1.48x ($37 million operating income against $25 million interest expense) means a modest EBITDA decline could pressure covenant and refinancing terms. Free cash flow is weak and lumpy — $103 million TTM, but Q3 2026 FCF was zero after $32 million capex against $32 million operating cash flow, and Q1 2026 FCF was -$12 million — so the company is not self-funding growth and still carries a dividend with a negative payout ratio of -0.21. Revenue concentration in challenged segments compounds this: the Q3 miss was attributed specifically to orthodontics and implants, the higher-multiple parts of the portfolio, while the mix tilts toward slower legacy consumables. Market and competitive risks center on valuation compression and share loss. The PS multiple has collapsed from over 7x in 2023 to 0.62x today, and while that limits further multiple compression, it also signals the market doubts margin recovery; a re-rating requires proof, not hope. Competition from Envista and Align in implants and clear-aligner-adjacent categories is intensifying, and soft dental demand is a macro-sensitive headwind — the stock's -42.64% peak-to-trough decline against a flat-to-up market implies materially higher volatility than the index, warranting smaller position sizing. Analyst sentiment reinforces the risk: Barclays remains Underweight and JP Morgan reiterated Neutral the day after the Q3 miss, with no upgrades in the visible window. The worst-case scenario is a chain in which orthodontics and implant share loss proves structural, FY revenue undershoots the $3.59 billion low estimate, EBITDA stays depressed, and refinancing costs rise — forcing a dividend cut and a fresh leg lower. From the current $9.16, a retest of the October 19 52-week low of $8.42 implies roughly -8%, while a breakdown below that floor (the $8.42-$8.56 support zone) could invite capitulation selling toward the low end of the analyst revenue range, implying a realistic downside of -15% to -25% in an adverse scenario.

FAQ

The most severe risk is balance-sheet fragility: debt-to-equity of 1.84x with total debt near 63% of capitalization and Q3 interest coverage of just 1.48x ($37 million operating income against $25 million interest expense) means a modest EBITDA decline could pressure refinancing terms, and a $29 million tax charge against $26 million pre-tax income already wiped out the quarter. Second is dividend sustainability — the payout ratio is -0.21 and Q3 2026 free cash flow was zero after $32 million of capex against $32 million of operating cash flow, so the 5.62% yield is less safe than it looks and a cut would likely trigger further selling. Third is competitive and structural risk: the Q3 miss was concentrated in orthodontics and implants, where Envista and Align are gaining share, and if that proves structural rather than cyclical the revenue base erodes below the $3.59 billion low estimate. Fourth is market and sentiment risk — the stock is down 16.35% over one year versus SPY's +12.27% (a -28.62 point relative-strength gap) with a -42.64% max drawdown, and analyst sentiment is skewed bearish with Barclays Underweight and no upgrades in the visible window, so momentum and downgrade risk remain live.

The 12-month forecast is split into three scenarios. The base case carries 55% probability with a $9.00-$11.50 range, assuming FY EPS near $1.25 and revenue near $3.65 billion, gross margin holding at 50-53%, and no sharp margin rebound — leaving the stock range-bound between the October low and the $11-$11.50 resistance area, supported by the 5.62% yield and 0.62x sales floor. The bear case at 25% probability targets $7.00-$8.42, requiring orthodontics and implant share loss to prove structural, FY revenue to undershoot $3.59 billion, and depressed EBITDA to force a dividend cut and costlier refinancing, breaking the $8.42-$8.56 support zone. The bull case at 20% probability targets $12.50-$14.27, requiring a cyclical trough, operating margin recovering toward the 9.13% Q2 2026 level from 4.43%, revenue near the $3.72 billion high estimate, and a multiple re-rating from 0.62x toward 1.0x-1.2x sales. The base case is most likely because the tight sub-5% EPS estimate spread signals analysts agree on near-term numbers even while ratings skew cautious.

On the metrics that remain meaningful, XRAY screens as deeply undervalued relative to its own history. The trailing PE of -3.81x and EV/EBITDA of -96.11x are unusable because trailing net income and EBITDA are negative, so price-to-sales at 0.62x is the cleanest signal — down from 2.11x in the Q3 2026 reported history, 2.37x at year-end 2025, and over 7x in 2023, a roughly 90% de-rating in three years. Price-to-book of 1.70x (versus 2.27x at end-2023) and price-to-cash-flow of 9.70x reinforce the discount, while the forward PE of 0.12x on the $1.25 consensus EPS is so low it mainly signals uncertainty about normalized earnings power rather than explosive growth expectations. Against profitable med-tech peers that typically command mid-teens to low-twenties earnings multiples, the discount is steep but justified by a -16.25% net margin and -44.63% ROE. The market is effectively pricing structural decline; if margins merely normalize, the stock is undervalued, but if orthodontics and implant share loss proves structural, the cheap multiple is a value trap rather than a bargain.

From a pure risk/reward standpoint XRAY is a speculative value proposition rather than a clean buy. The upside case rests on a 0.62x sales multiple that has collapsed from over 7x in 2023, a 5.62% dividend yield, and $103 million of TTM free cash flow, which together suggest the market has already priced severe pessimism; a re-rating toward even 1.0x sales would imply meaningful upside toward the $12.50-$14.27 zone. The downside is equally concrete: revenue is contracting 7.52% YoY to $836 million, the Q3 miss came from the highest-value orthodontics and implants segments, trailing EPS is -$0.26, and interest coverage of 1.48x leaves little cushion. With only two of ten recent analyst actions positive and no published consensus target, there is no Street anchor to lean on. It is a reasonable buy only for risk-tolerant investors with a multi-year horizon who can tolerate a retest of the $8.42 low (roughly -8%) or worse, and who size the position small; it is not a good buy for income investors who need dividend safety or for anyone requiring near-term earnings momentum.

XRAY is better suited to a patient, long-term value approach than to short-term trading. The company is a mature, challenged turnaround with contracting revenue (-7.52% YoY), negative trailing EPS of -$0.26, and a broken chart — down 20.97% over three months and 18.72% YTD — so the thesis depends on margin normalization and a multiple re-rating that will take several quarters to prove out; a concrete minimum holding period of 18-24 months aligns with the time needed for two to three earnings cycles of evidence. Short-term traders face a difficult setup: the 1-month bounce of +8.53% versus SPY's -2.26% faded from the November 4 spike to $10.65 back to $9.16, and with volume reported as zero there is no confirmation, so the bounce should be treated as suspect until price reclaims $10.50-$11.00. The 5.62% dividend yield offers some carry, but with a negative payout ratio and zero Q3 free cash flow it should not be relied upon as income. Position sizing should be modest given the -42.64% max drawdown and realized volatility well above the index.